secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0000886163-24-000047
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand reports Merck vaccine FDA approval milestone and Takeda soticlestat Phase 3 miss
--------------------------------------------------------------------------------

- FDA approved Merck's CAPVAXIVE; Ligand earns $2M milestone + royalties on net sales.
- Takeda's soticlestat missed primary endpoints in Dravet (SKYLINE) and Lennox-Gastaut (SKYWAY) Phase 3 trials.
- Ligand owns 13% royalty on soticlestat from $30M Ovid deal; clinical miss reduces royalty value.
- SKYLINE narrowly missed seizure reduction primary; showed significant secondary endpoint effects.
- SKYWAY missed primary endpoint of reduction in major motor drop seizures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/0000886163-24-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/lgnd-20240618.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer